Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone

American Journal of Gastroenterology

Volumn 96, Issue 4, 2001, Pages 1143-1149

  Min, Albert D ^a   Jones, Jennifer L ^b   Esposito, Stephen ^b   Lebovics, Edward ^b   Jacobson, Ira M ^b   Klion, Franklin M ^b   Goldman, Ira S ^b   Geders, Jane M ^b   Tobias, Hillel ^b   Bodian, Carol ^b   Bodenheimer Jr , Henry C ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; REBETRON; RIBAVIRIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART PALPITATION; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RASH;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 0035053578     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02255-9     Document Type: Article

References (45)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus
3. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma
4. Clinical outcomes after transfusion-associated hepatitis C
5. Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant
6. Liver transplantation for hepatitis C virus-related cirrhosis
7. Liver transplantation for chronic viral hepatitis
8. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
9. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C
10. Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis
11. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
12. Ribavirin treatment for chronic hepatitis C
13. Ribavirin as therapy for chronic hepatitis C
14. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
15. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
16. Randomized, double-blind, placebo- controlled trial of interferon alpha-2b with, and without ribavirin for chronic hepatitis C
17. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
18. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
19. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
20. Use of high-dose interferon in the treatment of chronic hepatitis C
21. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
22. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis
23. A controlled study to determine the optimal dose regimen of interferon-alfa-2b in chronic hepatitis C
24. Monitoring of serum levels of HCV RNA in early phase of IFN therapy as a predictive marker of subsequent response
25. Re-treatment of chronic hepatitis C with consensus interferon
26. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patients
27. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
28. Rising incidence of hepatocellular carcinoma in the United States
29. A pilot study of ribavirin therapy for chronic hepatitis C
30. Therapy of hepatitis C: Consensus interferon trials
31. Factors predictive of a beneficial response to therapy of hepatitis C
32. Standards of treatment in chronic hepatitis C
33. Therapy of hepatitis C: Retreatment with alpha interferon
34. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial
35. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
36. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience
37. Treatment with interferon-alpha 2a alone or interferon-alpha 2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha 2a
38. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: Results of a randomized multicenter trial
39. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
40. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
41. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
42. Interferon-alfa-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alfa alone: An Italian multicenter, randomized, controlled, clinical study
43. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
44. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C
45. Racial difference in response to therapy with interferon in chronic hepatitis C